CONSOLIDATED STATEMENTS OF CONTINGENTLY REDEEMABLE COMMON STOCK AND STOCKHOLDERS EQUITY - USD ($) $ in Thousands	Total	Contingently Redeemable Common Stock	Contingently Redeemable Common Stock IPO	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (loss)	Noncontrolling Interest
Beginning balance at Dec. 31, 2019	$ (232,028)			$ 2,467	$ 256,643	$ (491,138)
Beginning balance, shares at Dec. 31, 2019				246,743,000
Contingently Redeemable Common Stock, Beginning balance, shares at Dec. 31, 2019		69,860,000
Contingently Redeemable Common Stock, Beginning balance at Dec. 31, 2019		$ 281,000
Net income (loss)	$ (60,052)					(60,052)
Issuance of common stock, shares	1,200,000			1,235,000
Issuance of contingently redeemable common stock	$ (460)	$ 28,500			(460)
Issuance of contingently redeemable common stock, shares		6,341,000
Issuance of common stock	5,550			$ 13	5,537
Settlement of stock-based liabilities	1,500			$ 3	1,497
Settlement of stock-based liabilities, Shares				334,000
Repurchase of common stock	$ (6,742)			$ (15)	(6,727)
Repurchase of common stock, shares	(1,500,000)			(1,500,000)
Exercises and vesting of stock-based awards	$ 814			$ 26	788
Exercises and vesting of stock-based awards, Shares				2,562,000
Stock-based compensation expense	6,688				6,688
Contingently Redeemable Common Stock, Ending balance, shares at Dec. 31, 2020		76,201,000
Contingently Redeemable Common Stock, Ending balance at Dec. 31, 2020		$ 309,500
Ending balance at Dec. 31, 2020	(284,730)			$ 2,494	263,966	(551,190)
Ending balance, shares at Dec. 31, 2020				249,374,000
Net income (loss)	(406,787)					(406,487)		$ (300)
Reclassification of contingently redeemable common stock in connection with IPO, shares			(76,201,000)	76,201,000
Reclassification of contingently redeemable common stock in connection with IPO, value	309,500		$ (309,500)	$ 762	308,738
Issuance of common stock, shares				53,590,000
Issuance of common stock, value	1,163,133			$ 536	1,162,597
Issuance of common stock under partner physician group equity agreements upon IPO, shares				11,672,000
Issuance of common stock under partner physician group equity agreements upon IPO, value	268,467			$ 117	268,350
Exercises and vesting of stock-based awards	18,086			$ 92	17,994
Exercises and vesting of stock-based awards, Shares				9,258,000
Stock-based compensation expense	23,927				23,927
Ending balance at Dec. 31, 2021	$ 1,091,596			$ 4,001	2,045,572	(957,677)		(300)
Ending balance, shares at Dec. 31, 2021	400,095,000			400,095,000
Net income (loss)	$ (106,864)					(106,553)		(311)
Other comprehensive income (loss)	(5,560)						$ (5,560)
Shares withheld related to net share settlement, shares				(37,000)
Shares withheld related to net share settlement, amount	(831)				(831)
Exercises and vesting of stock-based awards	33,887			$ 119	33,768
Vesting of restricted stock units, shares				404,000
Vesting of restricted stock units, amount				$ 4	(4)
Exercises and vesting of stock-based awards, Shares				11,923,000
Stock-based compensation expense	28,381				28,381
Contingently Redeemable Common Stock, Ending balance, shares at Dec. 31, 2022		0
Contingently Redeemable Common Stock, Ending balance at Dec. 31, 2022		$ 0
Ending balance at Dec. 31, 2022	$ 1,040,609			$ 4,124	$ 2,106,886	$ (1,064,230)	$ (5,560)	$ (611)
Ending balance, shares at Dec. 31, 2022	412,385,000			412,385,000